Based on the Cassava Sciences stock price forecasts from 2 analysts, the average SAVA stock price target is USD 33.00 over the next 12 months. Cassava Sciences Inc’s average analyst rating is Sell. Stock Target Advisor’s own stock analysis of SAVA stock forecast is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, SAVA stock price was USD 19.82. SAVA stock price has changed by +1.32% over the past week, -4.46% over the past month and -81.81% over the last year.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer’s disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
What we like:
High market capitalization:
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior risk adjusted returns:
SAVA stock price has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.
What we don’t like:
The total returns for SAVA stock price are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced compared to book value:
SAVA stock price is trading high compared to its peers median on a price to book value basis.
SAVA stock forecast has shown negative total cash flow in the most recent four quarters.
Negative free cash flow:
SAVA stock forecast has shown negative total free cash flow in the most recent four quarters.
Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.